Eléments de l'association
|  |
List of bibliographic references
Number of relevant bibliographic references: 3.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 001F63 | A. P. Kengne [Australie] ; A. Patel [Australie] ; S. Colagiuri [Australie] ; S. Heller [Royaume-Uni] ; P. Hamet [Canada] ; M. Marre [France] ; C. Y. Pan [République populaire de Chine] ; S. Zoungas [Australie] ; D. E. Grobbee [Pays-Bas] ; B. Neal [Australie] ; J. Chalmers [Australie] ; M. Woodward [Australie, États-Unis] | The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study |
| 002177 | Q. Li [Australie] ; J. Chalmers [Australie] ; S. Czernichow [Australie, France] ; B. Neal [Australie] ; B. A. Taylor [Norvège] ; S. Zoungas [Australie] ; N. Poulter [Royaume-Uni] ; M. Woodward [Australie, États-Unis] ; A. Patel [Australie] ; B. De Galan [Australie, Pays-Bas] ; G. D. Batty [Australie, Royaume-Uni] | Oral disease and subsequent cardiovascular disease in people with type 2 diabetes: a prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial |
| 002C39 | B. E. De Galan [Australie, Pays-Bas] ; S. Zoungas [Australie] ; J. Chalmers [Australie] ; C. Anderson [Australie] ; C. Dufouil [France] ; A. Pillai [Australie] ; M. Cooper [Australie] ; D. E. Grobbee [Pays-Bas] ; M. Hackett [Australie] ; P. Hamet [Canada] ; S. R. Heller [Royaume-Uni] ; L. Lisheng [République populaire de Chine] ; S. Macmahon [Australie] ; G. Mancia [Italie] ; B. Neal [Australie] ; C. Y. Pan [République populaire de Chine] ; A. Patel [Australie] ; N. Poulter [Royaume-Uni] ; F. Travert [France] ; M. Woodward [Australie, États-Unis] | Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial |
| This area was generated with Dilib version V0.6.33. |  |